Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06696014 · ClinicalTrials.gov registry record

Mirikizumab Real World Protocol

A clinical trial of Ulcerative Colitis, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
100
Enrollment target
9
Study locations

NCT06696014 is a study of Ulcerative Colitis that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 100 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06696014, a study of Ulcerative Colitis, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
100 participants
Enrollment target
9
Study locations

Study Summary

The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of their regular medical care for UC will answer online survey questions about their bowel habits for 1 year.

Conditions Studied

Study Locations (9)

Colorado

  • South Denver Gastroenterology - Denver

Florida

  • AdventHealth - Orlando

Iowa

  • University of Iowa Health Care - Iowa City

Kentucky

  • University of Louisville, Clinical Trials Unit - Louisville

New York

  • University Of Rochester Medical Center - Rochester

North Carolina

  • University of North Carolina - Chapel Hill

South Carolina

  • Medical University of South Carolina (MUSC) - Charleston

Texas

  • Southern Star Research Institute, LLC - San Antonio

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-05-08
Est. Completion 2030-01

What the Registry Record Tells You About NCT06696014

The ClinicalTrials.gov registry entry for NCT06696014 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (95% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.

NCT06696014 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Colorado, Florida, Iowa.

Frequently Asked Questions

What is clinical trial NCT06696014 about?

NCT06696014 is a clinical study titled "Mirikizumab Real World Protocol". The goal of this observational study is to learn about how effective mirikizumab (Omvoh) is when treating patients with ulcerative colitis (UC) Does mirikizumab (Omvoh) lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed mirikizumab (Omvoh) as part of th...

What is the current status of trial NCT06696014?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2025-05-08. Estimated completion is 2030-01.

What conditions does trial NCT06696014 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

Who is sponsoring clinical trial NCT06696014?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06696014 being conducted?

This trial has 9 study locations across Colorado, Florida, Iowa, Kentucky, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.